Maxim Pharmaceuticals Receives Approval From FDA of a Treatment Protocol for Ceplene in Advanced Malignant Melanoma
14 avr. 2004 03h13 HE
|
Maxim Pharmaceuticals
SAN DIEGO, April 14, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its treatment protocol to provide its investigational drug Ceplene(TM), in combination...
Maxim Pharmaceuticals Presents Preclinical Results For Its Novel Vascular Targeting Agent MX116407
30 mars 2004 02h49 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, and SAN DIEGO, March 30, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced research results demonstrating the anti-cancer activity of the Company's...
Maxim Pharmaceuticals Completes Phase 1 Pharmacokinetic Trial of Orally Dosed Histamine
23 mars 2004 03h07 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden and SAN DIEGO, March 23, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that it has completed a Phase 1A pharmacokinetic trial of a new orally...
Maxim Pharmaceuticals Reacquires Rights To Mx2105 Preclinical Cancer Drug Candidate
17 mars 2004 03h01 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, March 17, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE: MAXM) today announced that it has entered into anagreement with Shire BioChem, Inc. under which Maxim has...
Maxim Pharmaceuticals Announces Publication of the Discovery and Characterization of Potent Anti-Cancer Compound
12 févr. 2004 03h12 HE
|
Maxim Pharmaceuticals
STOCKHOLM, Sweden, Feb. 12, 2004 (PRIMEZONE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) announced the publication of its manuscript entitled "Discovery, Characterization and SAR of Gambogic...